Miele & Cie KG v Bruckbauer [2025] FCA 1046
Date of decision:
28 August 2025
Body:
Federal Court of Australia
Adjudicator:
...Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Kimberley Evans, Helen Macpherson | Jan 16, 2026
Miele & Cie KG v Bruckbauer [2025] FCA 1046
Date of decision:
28 August 2025
Body:
Federal Court of Australia
Adjudicator:
...By Pearce IP | Jan 15, 2026
Pearce IP and Chantal Savage, have been ranked in Australia for Intellectual Property in the Legal 500 Asia Pacific 2026 Rankings.
Legal 500 rankings are so highly regarded du...
By Kimberley Evans, Helen Macpherson | Jan 14, 2026
Oxford Nanopore Technologies Plc v MGI Australia Pty Ltd (No 2) [2025] FCA 869
Date of decision:
29 July 2025
Body:
Federal Court of Aust...
By Naomi Pearce, Chantal Savage, Nathan Kan | Jan 13, 2026
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the last three weeks ending 9 January 2026 are ...
By Helen Macpherson, Nathan Kan | Jan 12, 2026
Newron Pharmaceuticals S.p.A v Arrotex Pharmaceuticals Pty Ltd (Application for Preliminary Discovery) [2025] FCA 1321
Date of decision:
29 October 20...
By Helen Macpherson, Nathan Kan | Jan 09, 2026
Scidera, Inc. v Meat and Livestock Australia Limited (No 2) [2025] FCA 1236
Date of decision:
10 October 2025
Body:
Federal Court
...
By Bioblast Editor | Jan 08, 2026
On 8 January 2026, Takeda announced that it has entered a global collaboration and licence agreement with Halozyme Therapeutics, Inc, which grants Takeda exclusive rights to Halozyme’s Enhanze® drug delivery technology for use with Takeda’s Entyvio® (vedolizumab).
Un...
By Bioblast Editor | Jan 08, 2026
On 8 January 2026, the Munich Regional Court granted Regeneron and Bayer preliminary injunctions (PIs) preventing STADA, Hexal, Celltrion and Advanz Pharma from marketing their aflibercept biosimilars in Germany and requiring them to recall any products already on the marke...
By Helen Macpherson, Nathan Kan | Jan 08, 2026
Dyno Nobel Asia Pacific Pty Ltd v Orica Explosives Technology Pty Ltd [2025] FCA 767
Date of decision:
14 July 2025
Body:
Federal Court
By Bioblast Editor | Jan 07, 2026
GSK’s Nucala® (mepolizumab) has received approval in China and the UK as an add-on maintenance treatment for adult patients with inadequately controlled COPD characterised by raised blood eosinophils.
The approval by China’s National Medical Products Administration (...
SUBSCRIBE TO PEARCE IP